Jiping Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiping Wang has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Andressa Dias Costa
Dana-Farber Cancer Institute 1 Department of Medical Oncology Harvard Medical School, Boston, Massachusetts
29 shared publications - Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
29 shared publications - Jonathan Andrew Nowak
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA
29 shared publications - Joseph D. Mancias
Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA
29 shared publications - Thomas E. Clancy
Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital/Mass General Brigham, Boston, USA
29 shared publications - Stephanie K. Dougan
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
20 shared publications
Latest Publications
Where does histotripsy fit into hepatocellular carcinoma care?
Histotripsy is a novel ultrasound‐guided ablation technique that has been approved by the US Food and Drug Administration as a medical device for the noninvasive destruction of liver tumors. The noninvasive, nonthermal, nonionizing mechanical mechanism by which it destroys tumor tissues makes it an appealing local therapy option in the treatment of patients with early‐stage hepatocellular carcinoma (HCC). In this article, the authors review the current evidence base for histotripsy in HCC and explore its potential role in routine care based on technical, safety, and clinical considerations. They then describe the evidence gaps that remain with respect to histotripsy’s treatment efficacy, comparative effectiveness, and safety relative to established local therapy options including thermal ablation, transarterial chemoembolization and radioembolization, and stereotactic body radiotherapy. Although the current body of evidence supports the technical feasibility, short‐term safety, and early local tumor control of histotripsy in the treatment of patients with HCC, standardized response assessments, rigorous prospective evaluations of durable oncologic outcomes, and direct comparisons with existing therapies in well‐defined patient populations are still needed before histotripsy can be fully integrated into standard HCC care.
Where does histotripsy fit into hepatocellular carcinoma care?
Histotripsy is a novel ultrasound‐guided ablation technique that has been approved by the US Food and Drug Administration as a medical device for the noninvasive destruction of liver tumors. The noninvasive, nonthermal, nonionizing mechanical mechanism by which it destroys tumor tissues makes it an appealing local therapy option in the treatment of patients with early‐stage hepatocellular carcinoma (HCC). In this article, the authors review the current evidence base for histotripsy in HCC and explore its potential role in routine care based on technical, safety, and clinical considerations. They then describe the evidence gaps that remain with respect to histotripsy’s treatment efficacy, comparative effectiveness, and safety relative to established local therapy options including thermal ablation, transarterial chemoembolization and radioembolization, and stereotactic body radiotherapy. Although the current body of evidence supports the technical feasibility, short‐term safety, and early local tumor control of histotripsy in the treatment of patients with HCC, standardized response assessments, rigorous prospective evaluations of durable oncologic outcomes, and direct comparisons with existing therapies in well‐defined patient populations are still needed before histotripsy can be fully integrated into standard HCC care.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity
Pancreatic ductal adenocarcinoma (PDAC) has been classified into classical and basal-like transcriptional subtypes by bulk RNA measurements. However, recent work has uncovered greater complexity to transcriptional subtypes than was initially appreciated using bulk RNA expression profiling. To provide a deeper understanding of PDAC subtypes, we developed a multiplex immunofluorescence (mIF) pipeline that quantifies protein expression of six PDAC subtype markers (CLDN18.2, TFF1, GATA6, KRT17, KRT5, and S100A2) and permits spatially resolved, single-cell interrogation of pancreatic tumors from resection specimens and core needle biopsies. Both primary and metastatic tumors displayed striking intratumoral subtype heterogeneity that was associated with patient outcomes, existed at the scale of individual glands, and was significantly reduced in patient-derived organoid cultures. Tumor cells co-expressing classical and basal markers were present in > 90% of tumors, existed on a basal-classical polarization continuum, and were enriched in tumors containing a greater admixture of basal and classical cell populations. Cell–cell neighbor analyses within tumor glands further suggested that co-expressor cells may represent an intermediate state between expression subtype poles. The extensive intratumoral heterogeneity identified through this clinically applicable mIF pipeline may inform prognosis and treatment selection for patients with PDAC.Significance:A high-throughput pipeline using multiplex immunofluorescence in pancreatic cancer reveals striking expression subtype intratumoral heterogeneity with implications for therapy selection and identifies co-expressor cells that may serve as intermediates during subtype switching.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity
Pancreatic ductal adenocarcinoma (PDAC) has been classified into classical and basal-like transcriptional subtypes by bulk RNA measurements. However, recent work has uncovered greater complexity to transcriptional subtypes than was initially appreciated using bulk RNA expression profiling. To provide a deeper understanding of PDAC subtypes, we developed a multiplex immunofluorescence (mIF) pipeline that quantifies protein expression of six PDAC subtype markers (CLDN18.2, TFF1, GATA6, KRT17, KRT5, and S100A2) and permits spatially resolved, single-cell interrogation of pancreatic tumors from resection specimens and core needle biopsies. Both primary and metastatic tumors displayed striking intratumoral subtype heterogeneity that was associated with patient outcomes, existed at the scale of individual glands, and was significantly reduced in patient-derived organoid cultures. Tumor cells co-expressing classical and basal markers were present in > 90% of tumors, existed on a basal-classical polarization continuum, and were enriched in tumors containing a greater admixture of basal and classical cell populations. Cell–cell neighbor analyses within tumor glands further suggested that co-expressor cells may represent an intermediate state between expression subtype poles. The extensive intratumoral heterogeneity identified through this clinically applicable mIF pipeline may inform prognosis and treatment selection for patients with PDAC.Significance:A high-throughput pipeline using multiplex immunofluorescence in pancreatic cancer reveals striking expression subtype intratumoral heterogeneity with implications for therapy selection and identifies co-expressor cells that may serve as intermediates during subtype switching.
Top advances of the year: Sarcoma
This article describes three advancements in sarcoma care in the past year, including a trial supporting immunotherapy in specific soft tissue sarcomas, Food and Drug Administration approval of a T‐cell therapy for synovial sarcoma, and long‐term efficacy data for a gamma‐secretase inhibitor in desmoid tumors. These advances represent a shift toward more effective, targeted treatments across a variety of challenging tumors.
Top advances of the year: Sarcoma
This article describes three advancements in sarcoma care in the past year, including a trial supporting immunotherapy in specific soft tissue sarcomas, Food and Drug Administration approval of a T‐cell therapy for synovial sarcoma, and long‐term efficacy data for a gamma‐secretase inhibitor in desmoid tumors. These advances represent a shift toward more effective, targeted treatments across a variety of challenging tumors.
- 20 May 2025
- Published by Springer Nature in Annals of Surgical Oncology
Robot-Assisted Transduodenal Sphincteroplasty for Ampullary Stenosis After Roux-en-Y-Gastric Bypass
Ampullary stenosis can be a late complication of Roux-en-Y gastric bypass (RYGB) causing biliary dyskinesia from ampullary sphincter hypertension (Heetun et al. in Eur J Gastroenterol Hepatol 23:327-333, 2011). Endoscopic management has limited efficacy with Roux anatomy. Thus, pancreatoduodenectomy (PD) may be performed (Wisneski et al. in HPB 22:1496-1503, 2020). In select cases, the morbidity of PD could be avoided using a transduodenal sphincteroplasty.In this report, the case of a patient with ampullary stenosis after RYGB is described. After multiple endoscopic attempts failed to produce durable symptom relief, operative intervention was considered. Choledocho-duodenostomy was deemed technically feasible, but because this patient had preoperative imaging showing that the patient's pancreatic duct communicated independently from the common bile duct (CBD) with the duodenum, robot-assisted transduodenal sphincteroplasty was the selected approach. With this procedure, an extended Kocher maneuver is required for adequate exposure. The lateral duodenal wall is anchored to the falciform ligament using a 2-0 absorbable stitch for retraction. A longitudinal duodenotomy is created along the duodenal wall opposite the major papilla. An 8-Fr catheter inserted through the ampulla into the CBD serves as a probe. Sphincterotomy is performed with electrocautery at the 11 o'clock position, dividing the ampullary sphincter until the CBD wall separates from the duodenal mucosa. A duct-to-mucosa anastomosis is performed using a 5-0 absorbable suture over the 8-Fr catheter, which is left in place: two stitches retracted from the superior CBD facilitate exposure. The duodenotomy is closed transversely with a 3-0 locking absorbable suture in two layers, and a leak test is performed.The patient began oral intake the day after surgery. An upper GI showed no leak on postoperative day 2, and thus the patient was discharged home receiving a liquid diet on postoperative day 3.
- 20 May 2025
- Published by Springer Nature in Annals of Surgical Oncology
Robot-Assisted Transduodenal Sphincteroplasty for Ampullary Stenosis After Roux-en-Y-Gastric Bypass
Ampullary stenosis can be a late complication of Roux-en-Y gastric bypass (RYGB) causing biliary dyskinesia from ampullary sphincter hypertension (Heetun et al. in Eur J Gastroenterol Hepatol 23:327-333, 2011). Endoscopic management has limited efficacy with Roux anatomy. Thus, pancreatoduodenectomy (PD) may be performed (Wisneski et al. in HPB 22:1496-1503, 2020). In select cases, the morbidity of PD could be avoided using a transduodenal sphincteroplasty.In this report, the case of a patient with ampullary stenosis after RYGB is described. After multiple endoscopic attempts failed to produce durable symptom relief, operative intervention was considered. Choledocho-duodenostomy was deemed technically feasible, but because this patient had preoperative imaging showing that the patient's pancreatic duct communicated independently from the common bile duct (CBD) with the duodenum, robot-assisted transduodenal sphincteroplasty was the selected approach. With this procedure, an extended Kocher maneuver is required for adequate exposure. The lateral duodenal wall is anchored to the falciform ligament using a 2-0 absorbable stitch for retraction. A longitudinal duodenotomy is created along the duodenal wall opposite the major papilla. An 8-Fr catheter inserted through the ampulla into the CBD serves as a probe. Sphincterotomy is performed with electrocautery at the 11 o'clock position, dividing the ampullary sphincter until the CBD wall separates from the duodenal mucosa. A duct-to-mucosa anastomosis is performed using a 5-0 absorbable suture over the 8-Fr catheter, which is left in place: two stitches retracted from the superior CBD facilitate exposure. The duodenotomy is closed transversely with a 3-0 locking absorbable suture in two layers, and a leak test is performed.The patient began oral intake the day after surgery. An upper GI showed no leak on postoperative day 2, and thus the patient was discharged home receiving a liquid diet on postoperative day 3.
- Open Access
- 25 June 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (7) , 114410
Arginine catabolism is essential to polymyxin dependence in Acinetobacter baumannii
- 25 June 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (7) , 114410
Open AccessArginine catabolism is essential to polymyxin dependence in Acinetobacter baumannii
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Table S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Table S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer